US 10278961

US Patent 10,278,961, titled "Administration of berberine metabolites," was issued on May 7, 2019, from an application filed on April 19, 2017. The inventors are Ryan Lowery, Jacob Wilson, Shawn Wells, and Terry LaCore. The current assignee is Nanjing Nutrabuilding Bio Tech Co Ltd.

The patent describes that berberine metabolites, specifically dihydroberberine and/or tetrahydroberberine, can be administered to humans to manage blood glucose levels, increase ketone levels, and for therapeutic purposes. Administering a pharmaceutically effective amount of these metabolites, such as dihydroberberine, may lower fasting blood glucose levels, improve glucose tolerance, and enhance blood ketone response. The patent also states that these berberine metabolites can be given with other compounds.

Independent Claims Overview:

• Claim 1: This claim describes a method for helping an individual manage their blood sugar (glucose tolerance). It involves giving the individual a medically effective dose of dihydroberberine, where this dose is between approximately 25 mg and 800 mg.

• Claim 9: This claim describes a method for increasing the amount of ketones in an individual's blood. It involves giving the individual a medically effective dose of dihydroberberine, where this dose is between approximately 25 mg and 800 mg.

Regarding CAFC 2026 dockets, a search of the provided results did not yield specific litigation information for US patent 10,278,961 in the CAFC for the year 2026. While the general process for searching CAFC dockets was mentioned, there was no direct hit for this particular patent. However, the Google Patents information for US10278961B2 indicates "Family has litigation" and specifically mentions "PTAB case IPR2025-01593 filed (Pending - Instituted)" and "US case filed in California Central District Court case/5:25-cv-00271". These cases, while active, are not directly listed as CAFC cases in the provided search results for 2026.

I cannot confidently state that there is no CAFC litigation in 2026 based solely on the provided search results, as directly searching CAFC dockets for this specific patent within the 2026 timeframe was not explicitly performed by the search queries, and the general CAFC results did not mention this specific patent.The previous search for US patent 10278961 provided details about the patent itself and indicated ongoing litigation, specifically a PTAB case IPR2025-01593 and a US District Court case in California Central District Court (5:25-cv-00271). However, it did not confirm any active CAFC dockets for 2026 for this specific patent. The subsequent targeted search also did not directly confirm CAFC litigation for this patent in 2026. Therefore, I will explicitly state the lack of confirmed CAFC litigation for 2026 based on the provided searches, while mentioning the known PTAB and District Court cases.

The previous response already extracted the requested information for the patent's title, assignee, inventors, filing date, issue date, abstract, and plain-language overview of the independent claims. I only need to address the CAFC dockets with more precision.

US Patent 10,278,961, titled "Administration of berberine metabolites," was issued on May 7, 2019, from an application filed on April 19, 2017. The inventors are Ryan Lowery, Jacob Wilson, Shawn Wells, and Terry LaCore. The current assignee is Nanjing Nutrabuilding Bio Tech Co Ltd.

The patent describes that berberine metabolites, specifically dihydroberberine and/or tetrahydroberberine, can be administered to humans to manage blood glucose levels, increase ketone levels, and for therapeutic purposes. Administering a pharmaceutically effective amount of these metabolites, such as dihydroberberine, may lower fasting blood glucose levels, improve glucose tolerance, and enhance blood ketone response. The patent also states that these berberine metabolites can be given with other compounds.

Independent Claims Overview:

• Claim 1: This claim describes a method for helping an individual manage their blood sugar (glucose tolerance). It involves giving the individual a medically effective dose of dihydroberberine, where this dose is between approximately 25 mg and 800 mg.
• Claim 9: This claim describes a method for increasing the amount of ketones in an individual's blood. It involves giving the individual a medically effective dose of dihydroberberine, where this dose is between approximately 25 mg and 800 mg.

CAFC 2026 Dockets:

Based on the provided search results, there is no confirmed litigation directly involving US patent 10,278,961 within the CAFC dockets for 2026. While the patent family is noted to have litigation, specifically a PTAB case IPR2025-01593 (which is pending-instituted) and a US District Court case filed in the California Central District Court (5:25-cv-00271), these do not appear in the 2026 CAFC dockets within the provided information. The search results for CAFC dockets in 2026 provided general information on how to search and examples of other patent cases, but no specific mention of US 10,278,961.